Orrick Herrington & Sutcliffe is expanding its life sciences group with the addition of David Schulman, who co-led the same practice area for Dechert.
Schulman has advised Celgene Corp., Ferring Pharmaceuticals SA, Adocia SAS and Pfizer Inc., among others, on transactions. He recently took the lead on BioAtla Inc.’s $72 million series D financing.
“We’re obviously attracted to David, just given his prominence and excellent reputation in the market as just being a top-tier practitioner,” said Matthew Gemello, head of Orrick’s global corporate practice.
The hire advances Orrick’s priority of building out the life sciences practice. In 2019, it brought ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.